MX2021004728A - Nuevos derivados aminofosfinicos como inhibidores de aminopeptidasa a. - Google Patents

Nuevos derivados aminofosfinicos como inhibidores de aminopeptidasa a.

Info

Publication number
MX2021004728A
MX2021004728A MX2021004728A MX2021004728A MX2021004728A MX 2021004728 A MX2021004728 A MX 2021004728A MX 2021004728 A MX2021004728 A MX 2021004728A MX 2021004728 A MX2021004728 A MX 2021004728A MX 2021004728 A MX2021004728 A MX 2021004728A
Authority
MX
Mexico
Prior art keywords
compound
novel
aminopeptidase
inhibitors
relates
Prior art date
Application number
MX2021004728A
Other languages
English (en)
Inventor
Catherine Llorens-Cortes
Fabrice Balavoine
Delphine Compere
Original Assignee
Quantum Genomics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quantum Genomics filed Critical Quantum Genomics
Publication of MX2021004728A publication Critical patent/MX2021004728A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/303—Cycloaliphatic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un nuevo compuesto, a una composición que comprende el mismo, a métodos para preparar el compuesto y al uso de este compuesto en terapia. En particular, la presente invención se refiere al compuesto que es útil en el tratamiento y prevención de hipertensión arterial primaria y secundaria, ictus, isquemia miocárdica, insuficiencia cardíaca y renal, infarto al miocardio, enfermedad vascular periférica, proteinuria diabética, síndrome X y glaucoma.
MX2021004728A 2018-10-26 2019-10-25 Nuevos derivados aminofosfinicos como inhibidores de aminopeptidasa a. MX2021004728A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306398 2018-10-26
PCT/EP2019/079288 WO2020084147A1 (en) 2018-10-26 2019-10-25 Novel aminophosphinic derivatives as aminopeptidase a inhibitors

Publications (1)

Publication Number Publication Date
MX2021004728A true MX2021004728A (es) 2021-10-13

Family

ID=64267738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004728A MX2021004728A (es) 2018-10-26 2019-10-25 Nuevos derivados aminofosfinicos como inhibidores de aminopeptidasa a.

Country Status (15)

Country Link
US (1) US20210309677A1 (es)
EP (1) EP3870590A1 (es)
JP (1) JP7137010B2 (es)
KR (1) KR102380036B1 (es)
CN (1) CN113166180A (es)
AR (1) AR116854A1 (es)
AU (1) AU2019364708B2 (es)
BR (1) BR112021007041A2 (es)
CA (1) CA3113391A1 (es)
EA (1) EA202191151A1 (es)
IL (1) IL282484B (es)
MX (1) MX2021004728A (es)
TW (1) TW202029965A (es)
WO (1) WO2020084147A1 (es)
ZA (1) ZA202103581B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202029962A (zh) * 2018-10-26 2020-08-16 法商量子基因科技有限公司 胺肽酶a抑制劑及包含其的醫藥組合物
TW202207917A (zh) * 2020-05-06 2022-03-01 法商量子基因科技有限公司 包含腦胺肽酶抑制劑、利尿劑及全身性腎素－血管收縮素系統阻斷劑之醫藥組合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773712B1 (fr) 1998-01-16 2000-06-02 Inst Nat Sante Rech Med Composition pharmaceutique comprenant au moins un inhibiteur de l'aminopeptidase a
US20140271926A1 (en) * 2013-03-12 2014-09-18 California Institute Of Technology Methods of use of glutamine synthetase inhibitors
TW202029962A (zh) * 2018-10-26 2020-08-16 法商量子基因科技有限公司 胺肽酶a抑制劑及包含其的醫藥組合物

Also Published As

Publication number Publication date
US20210309677A1 (en) 2021-10-07
EP3870590A1 (en) 2021-09-01
TW202029965A (zh) 2020-08-16
CN113166180A (zh) 2021-07-23
IL282484B (en) 2022-03-01
AU2019364708B2 (en) 2021-07-29
IL282484A (en) 2021-06-30
AR116854A1 (es) 2021-06-23
CA3113391A1 (en) 2020-04-30
KR102380036B1 (ko) 2022-03-28
AU2019364708A1 (en) 2021-04-29
BR112021007041A2 (pt) 2021-07-20
WO2020084147A1 (en) 2020-04-30
JP2021535188A (ja) 2021-12-16
JP7137010B2 (ja) 2022-09-13
EA202191151A1 (ru) 2021-07-15
ZA202103581B (en) 2022-08-31
KR20210090636A (ko) 2021-07-20

Similar Documents

Publication Publication Date Title
MX2021004741A (es) Inhibidores de aminopeptidasa a y composiciones farmacéuticas que comprenden el mismo.
MX2021003460A (es) Fabricacion de compuestos y composiciones para inhibir la actividad de shp2.
MX2021006026A (es) Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
MX2021003459A (es) Proceso de fabricacion de un compuesto para la inhibicion de la actividad de shp2.
JOP20180009A1 (ar) مركبات مثبط فيروس hiv
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
MX2021004728A (es) Nuevos derivados aminofosfinicos como inhibidores de aminopeptidasa a.
EA201290632A1 (ru) Производные бетулина
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
ZA202109193B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
NZ746906A (en) Oxaborole esters and uses thereof
MX2022002398A (es) Formas cristalinas de un inhibidor de cd73.
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
CR20210460A (es) Compuestos útiles en la terapia del vih
AU2020235187A8 (en) Uses of phosphodiesterase inhibitors
MX2022013273A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus metodos de uso.
MX2022006945A (es) Tratamientos para el edema macular diabetico y la agudeza visual disminuida.
MX2021014773A (es) Formas de sales cristalinas de un inhibidor de cinasas.
MX2023007554A (es) Compuesto espirocíclico como inhibidor del homólogo del oncogén viral del sarcoma 2 de rata de kirsten con mutación g12c (kras-g12c).
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.